COVID-19 In the Pipeline Therapeutics

Target Audience
This activity is intended for health care providers in the care of patients with COVID-19.
This activity is supported by independent educational grants from Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., and Eli Lilly and Company.

Program Overview:
In this on-demand video webinar, Dr. Paul Auwaerter discusses potential COVID-19 treatments currently in the pipeline. Topics:
Outpatient treatments: inhaled remdesivir, oral antivirals, inhaled budesonide, and monoclonal antibodies
Inpatient treatments: lenzilumab, baricitinib, and dexamethasone
Clinical progression, risk factors, and home care for COVID-19 patients

Learning Objectives
After completing this activity, the participant should be better able to:
Appraise the efficacy, safety and indications for treatments for patients with COVID requiring hospitalization.
Evaluate management strategies for outpatients with mild to moderate COVID-19.
Explain mechanisms of action of monoclonal antibodies (mAbs) and other current and in-development treatments for COVID-19.
Describe best practices for managing patients with COVID-19 with mAbs and other agents.